Doximity Q1 2027 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $157 million, up 7% year-over-year, exceeding guidance by 3%.

Adjusted EBITDA: $75 million, representing a 48% margin, beating guidance by 8%.

Net Revenue Retention (NRR): Overall NRR at 107%, with top 20 customers at 112%.

GAAP EPS: $0.13 per share; Non-GAAP EPS: $0.29 per share.

Cash Position: $688 million in cash and marketable securities; debt-free.

Free Cash Flow: $40 million generated in Q1, down from the previous year due to timing fluctuations in collections.

2Strategic Updates and Business Highlights

AI Investment: Doximity is focusing heavily on AI, with plans to expand AI capabilities and usage across its platform, leveraging a unique built-in drug reference and a network of 12,000 physician editors.

Clinical AI Performance: Doximity Ask ranked highest in an independent study (NOHARM) for clinical AI models, showcasing low error rates and high safety ratings.

Client Growth: 165 signed health system AI clients, including major hospitals like Northwestern and Penn Medicine.

AI Product Adoption: Over 30% year-on-year growth in quarterly active workflow prescribers, with significant increases in AI tool usage.

3Forward Guidance and Outlook

Q2 2027 Revenue Guidance: Expected between $170 million and $171 million, reflecting a modest year-over-year growth.

Full Year 2027 Revenue Guidance: Revised upward to between $671 million and $681 million, representing 5% growth at the midpoint.

Adjusted EBITDA for Q2: Expected between $80.5 million and $81.5 million, maintaining a 48% margin.

Long-term AI Strategy: Continued investment in AI expected to drive future growth, with a focus on scaling AI search and improving monetization.

4Bad News, Challenges, or Points of Concern

Market Environment: The overall pharma spending environment remains tight, although more stable than before.

Gross Margin Pressure: Non-GAAP gross margin decreased to 88% from 91% year-over-year due to increased AI compute spending and operational costs.

Regulatory Risks: Concerns about the liability associated with AI outputs are rising, particularly as lawsuits related to AI usage in healthcare begin to emerge.

Competitive Landscape: The AI market is rapidly evolving, and Doximity faces competition from other clinical AI vendors, necessitating ongoing innovation and differentiation.

5Notable Q&A Insights

Impact of NOHARM Study: The study's results are expected to enhance trust and usage among physicians, positioning Doximity favorably against competitors.

AI Budget Dynamics: While the overall budget growth for pharma remains tight, Doximity is seeing opportunities in AI innovation budgets, with a significant portion of pharma buyers expressing intent to allocate funds to AI.

AI Search Monetization: The monetization of AI search is anticipated to ramp up as more health systems adopt Doximity Ask, with the potential for increased revenue as user engagement grows.

User Engagement: Doximity's strong relationship with its users is highlighted as a key differentiator, with significant increases in AI tool usage indicating a positive trend in engagement. This summary encapsulates the key aspects of Doximity's Q1 2027 earnings call, reflecting both the company's achievements and the challenges it faces in a competitive and evolving market.